I agree. It seemed like it would be pretty easy to bring back to the market. Investigate what caused it, manufacturing issues, dialysis center issue or omontys itself. When they determine it was Omntys set up a plan to determine which patients may experience allegic reactions and exclude them from taking the drug. This should not take over a year. But if the FDA wants them to fix the issue that occured on .2% of patients then that will never get resolved. I guess Takeda is not giving up on seeing what they can come up with. Since there is a drug out there that aready works the FDA sees no reason to bring back Omontys unless the issue of allergic reactions is resolved. I know other anemia drugs cause allergic reactions, it would be nice to know the percentage of patients that have allergic reactions from the other anemia drugs. I sold all my shares today at a loss, good luck to everyone still holding.
I have looked everywhere to find this info and nothing is coming up. Can you or anybody please attach a link or at least where you got the info from. If this info is valid then I will definitely buy more shares.
A link would be greatly appreciated, could not find any info when searching. Any idea on the timeframe these tests would take? This is definitely the right route to take to get Omontys back on the market. There is no way Takeda would take this route if there was no chance for Omontys.